KarmaliRN, BushC, RamanSR, et al.: Long-term opioid therapy definitions and predictors: A systematic review. Pharmacoepidemiol Drug Saf, 2020; 29:252–269.
2.
SemenkovichK, ChockalingamR, ScherrerJF, et al.: Prescription opioid analgesics increase risk of major depression: New evidence, plausible neurobiological mechanisms and management to achieve depression prophylaxis. Mo Med, 2014; 111:148–154.
3.
KoobGF: Neurobiology of opioid addiction: Opponent process, hyperkatifeia, and negative reinforcement. Biol Psychiatry, 2020; 87:44–53.
4.
ScherrerJF, AhmedaniB, AutioK, et al.: The Prescription Opioids and Depression Pathways Cohort Study. J Psychiatr Brain Sci, 2020; 5:1–15.
5.
ManhapraA, SullivanMD, BallantyneJC, et al.: Complex persistent opioid dependence with long-term opioids: A gray area that needs definition, better understanding, treatment guidance, and policy changes. J Gen Intern Med, 2020; 35:964–971.
6.
ManhapraA, AriasAJ, BallantyneJC: The conundrum of opioid tapering in long-term opioid therapy for chronic pain: A commentary. Subst Abus, 2018; 39:152–161.
7.
DavisMP, DigwoodG, MehtaZ, McPhersonML: Tapering opioids: A comprehensive qualitative review. Ann Palliat Med, 2020; 9:586–610.
ScherrerJF, SalasJ, SchneiderFD, et al.: Characteristics of new depression diagnoses in patients with and without prior chronic opioid use. J Affect Disord, 2017; 210:125–129.
10.
ShurmanJ, KoobGF, GutsteinHB: Opioids, pain, the brain, and hyperkatifeia: A framework for the rational use of opioids for pain. Pain Med, 2010; 11:1092–1098.
11.
KoobGF, Le MoalM: Drug abuse: Hedonic homeostatic dysregulation. Science, 1997; 278:52–58.
12.
KerteszSG, ManhapraA: The drive to taper opioids: Mind the evidence, and the ethics. Spinal Cord Series Cases, 2018; 4:64.
13.
GoeldnerC, LutzPE, DarcqE, et al.: Impaired emotional-like behavior and serotonergic function during protracted abstinence from chronic morphine. Biol Psychiatry, 2011; 69:236–244.
14.
ScherrerJF, SalasJ, SullivanMD, et al.: Impact of adherence to antidepressants on long-term prescription opioid use cessation. Br J Psychiatry, 2018; 212:103–111.
15.
CaseAA, WalterM, PaillerM, et al.: A practical approach to nonmedical opioid use in palliative care patients with cancer: Using the PARTNERS Framework. J Pain Symptom Manage, 2020; 60:1253–1259.
16.
ChouR, BallantyneJ, LembkeA: Rethinking opioid dose tapering, prescription opioid dependence, and indications for buprenorphine. Ann Intern Med, 2019; 171:427–429.
17.
SherL: Buprenorphine and the treatment of depression, anxiety, non-suicidal self-injury, and suicidality. Acta Psychiatr Scand, 2016; 134:84–85.
18.
OckerAC, ShahNB, SchwenkES, et al.: Ketamine and cognitive behavioral therapy for rapid opioid tapering with sustained opioid abstinence: A case report and 1-year follow-up. Pain Pract, 2020; 20:95–100.
19.
LoggeWB, MorrisRW, BaillieAJ, et al.: Baclofen attenuates fMRI alcohol cue reactivity in treatment-seeking alcohol dependent individuals. Psychopharmacology (Berl) 2019.
20.
SwiftR: Medications acting on the dopaminergic system in the treatment of alcoholic patients. Curr Pharm Des, 2010; 16:2136–2140.
21.
KhojainovaN, Santiago-PalmaJ, KornickC, et al.: Olanzapine in the management of cancer pain. J Pain Symptom Manage, 2002; 23:346–350.
